德国拜耳利伐沙班治疗什么病

What diseases does Bayer of Germany mainly produce to treat? Rivaroxaban is mainly used clinically to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

In 1863, Bayer AG was founded in Germany by Friedrich Bayer. The company is headquartered in Leverkusen, Germany, and has 750 production plants in 200 locations on five continents; it has 120,000 employees and 350 branches in almost all countries around the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. With more than 10,000 product categories, the company is Germany's largest industrial group. Bayer's development history is its continuous pursuit of a higher quality of life.

Indications for rivaroxaban are:

1. For use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets.

In terms of taking: Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15 mg or 20 mg tablets should be taken with food. For the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery, the recommended dose of oral rivaroxaban is 10 mg once daily.

If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery. For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, the patient should take it immediately and continue taking the dose once daily the next day. To treat DVT and reduce the risk of acute DVT recurrence and PE, the recommended dose for initial treatment of acute DVT is 15 mg twice a day for the first three weeks, and then the dose for maintenance treatment and to reduce the risk of DVT recurrence and PE is 20 mg once a day.

Recommended related hot articles: /newsDetail/90168.html